Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and willingly sign a consent form before any study procedures begin
• People aged 18 to 75 years old at the time of signing the consent form
• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by laboratory testing of tissue or cell samples
• People who have not previously received systemic (whole-body) treatment for advanced or spreading pancreatic cancer; those who received earlier chemotherapy or radiation aimed at curing the disease may still be eligible if at least 6 months have passed since their last treatment and the cancer has since progressed
• People who have at least one measurable tumour that can be tracked according to standard imaging guidelines
• People who are largely able to carry out daily activities, with little or no limitation due to their illness (confirm with trial site)
• People whose doctors expect them to survive at least 3 months
• People whose heart, liver, kidneys, and other organs are functioning well enough to participate (confirm with trial site)
• Women who could become pregnant must have a negative blood pregnancy test within 7 days before the first dose, and both female participants and male participants with partners who could become pregnant must use effective contraception during the study and for 120 days after the last dose

Who may not be able to join:

• People diagnosed with a different type of pancreatic cancer, such as acinar cell carcinoma, pancreatic neuroendocrine tumours, or pancreatoblastoma
• People with known active or untreated cancer that has spread to the brain, spinal cord, or the membranes surrounding the brain or spinal cord
• People with a known inherited (germline) mutation in the BRCA1 or BRCA2 genes
• People with fluid build-up in the chest, around the heart, or in the abdomen that requires draining more than once a month
• People whose cancer appears to be deteriorating rapidly at the time of screening, in the judgement of the study doctor
• People who have had another active cancer within the past 3 years, other than certain localised cancers that have been fully treated and cured
• People who have had major surgery (unrelated to the pancreatic cancer diagnosis) within 28 days before the first dose, or who are expected to need major surgery during the study
• Women who are pregnant or breastfeeding
• People who have previously received treatments that work by targeting the immune system's response to tumours
• People with known reasons why they cannot safely receive the chemotherapy drugs planned for this trial
• People with a known history of severe allergic reactions to monoclonal antibody medicines or intravenous immunoglobulin treatments
• People who have had an active autoimmune disease within the 2 years before starting the study
• People with active pulmonary tuberculosis (TB in the lungs)
• People with active hepatitis B or active hepatitis C infection
• People with a known immune deficiency condition or a positive HIV test
• People who have an active infection at the time of joining
• People who have previously received an organ transplant or a stem cell transplant from a donor
• People who are currently taking part in another clinical trial that involves an active treatment or intervention
• People who have any other condition that the study doctor believes could make participation unsafe or affect the reliability of the study results

Important: Always verify eligibility with the trial site directly before applying.